Renalytix falls 8% as further funding may be needed
Renalytix Plc (RNLXY) Shareholder/Analyst Call Transcript
Renalytix shares surge 19% as trading resumes after cash call
KidneyIntelX® Delivers Unprecedented Two-Year Real-World Outcomes in Diabetic Kidney Disease: No Comparable Risk Assessment Tool Exists
Renalytix shares climb 24% as two-year kidney study data published
Renalytix™ and Carna Health Partner to Solve Kidney Disease Crisis: Bridging the Existing Gap Between Population Screening and Precision Intervention
Renalytix shares fall 25% as revenues miss expectations
Pivotal kidneyintelX.dkd Data Published in Diabetes Care, Considered the Leading Clinical Journal Worldwide in Diabetes
MVP Health Care and Renalytix Partner to Bring Life-Changing Kidney Disease Testing to Local Communities
Renalytix Plc (RNLXY) Q2 2025 Earnings Call Transcript
Renalytix plc Reports Financial Results for First Quarter of Fiscal Year 2025
Warning: RNLXY is at high risk of performing badly
Renalytix and Steno Diabetes Center Announce Precision Medicine Collaboration Marking First Expansion for KidneyIntelX Platform Beyond US
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.
